



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board
Thursday, September 9, 2021, 1:00pm

Phone number for Audio Only: 866-692-4530

Access Code: 161 111 1426

Agenda

1. **Call to Order and Introductions** – John Morgan, MD, Chief Clinical Innovation Officer, Chair
2. **Minutes** - Approval of Minutes from June 10, 2021 meeting
3. **New Drugs** - Grid
 - a) Empaveli™ (pegcetacoplan)
 - b) Fotivda® (tivozanib) *
 - c) Lumakras™ (sotorasib) **
 - d) Myfembree® (relugolix, estradiol, and norethindrone acetate)
 - e) Nextstellis® (drospirenone and estetrol tablets)
 - f) Truseltiq™ (infigratinib)
 - g) Wegovy™ (semaglutide)
 - h) Zegalogue® (dasiglucagon)
4. **Class Criteria**
 - a) Hepatitis C
 - b) Oral Hypoglycemic
 - c) Oral Oncology – Lung Cancer **
 - d) Oral Oncology – Renal Cell Carcinoma *



COMMONWEALTH of VIRGINIA
Department of Medical Assistance Services
DRUG UTILIZATION REVIEW PROGRAM

- 5. MRx Pipeline/DUR Quarterly Newsletter – Available on WebPortal**
- 6. Surveillance**
 - a) Opioid Use with Risk Factors with and without Naloxone
 - b) Synagis
- 7. Reports**
 - a) ProDUR
 - b) RetroDUR
 - i. Recent RetroDUR Activity
 - ii. RetroDUR Criteria Estimates
 - c) Utilization Analysis
- 8. Other Business**
 - a) teplizumab
- 9. Adjournment**